New Normal Environment is emerging in the
biopharmaceutical and medical technology sectors. After a wave of merger activity in recent years, Big Pharma is realigning its strategic priorities. The new reality is a scarcity of early stage venture funds. Facing a tough reality, biotech ventures must
find effective ways to redesign their strategies and improve their capabilities to survive and thrive. This programme is designed for executives who are looking for new solutions.
The key takeaway: learning how to do business development more effectively.
hgh
Key objectives of this programme are:
jh
- Global overview on trends and tools for facing changes and developing strategies for growing your business in the biomedical sector.
- Key elements to foster high potentials teams to maximize their capabilities and outputs at any level.
- A pool of experiences of international entrepreneurs and executive managers in redesigning company strategies in the biopharmaceutical industry.